STAT Family of Transcription Factors in Breast Cancer: Pathogenesis and Therapeutic Opportunities and Challenges

Overview

Journal Semin Cancer Biol

Specialty Oncology

Date 2022 Aug 22

PMID 35995341

Authors

Grace L Wong

Sara G Manore

Daniel L Doheny

Hui-Wen Lo

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most commonly diagnosed cancer and second-leading cause of cancer deaths in women. Breast cancer stem cells (BCSCs) promote metastasis and therapeutic resistance contributing to tumor relapse. Through activating genes important for BCSCs, transcription factors contribute to breast cancer metastasis and therapeutic resistance, including the signal transducer and activator of transcription (STAT) family of transcription factors. The STAT family consists of six major isoforms, STAT1, STAT2, STAT3, STAT4, STAT5, and STAT6. Canonical STAT signaling is activated by the binding of an extracellular ligand to a cell-surface receptor followed by STAT phosphorylation, leading to STAT nuclear translocation and transactivation of target genes. It is important to note that STAT transcription factors exhibit diverse effects in breast cancer; some are either pro- or anti-tumorigenic while others maintain dual, context-dependent roles. Among the STAT transcription factors, STAT3 is the most widely studied STAT protein in breast cancer for its critical roles in promoting BCSCs, breast cancer cell proliferation, invasion, angiogenesis, metastasis, and immune evasion. Consequently, there have been substantial efforts in developing cancer therapeutics to target breast cancer with dysregulated STAT3 signaling. In this comprehensive review, we will summarize the diverse roles that each STAT family member plays in breast cancer pathobiology, as well as, the opportunities and challenges in pharmacologically targeting STAT proteins and their upstream activators in the context of breast cancer treatment.

Citing Articles

Single-Cell RNA Sequencing Reveals Extensive Heterogeneity and Unique Gene Trajectories in Non-Transformed and Transformed Human Lung Epithelial Cells: Insights into the Role of LncRNAs in Tumor Heterogeneity.

Moeng S, Chamorro-Parejo A, Jeon M, Cai J, Ramos K Int J Mol Sci. 2025; 26(4).

PMID: 40004153 PMC: 11855061. DOI: 10.3390/ijms26041690.

Roles of Post-Translational Modifications of Transcription Factors Involved in Breast Cancer Hypoxia.

Seymour L, Nuru N, Johnson K, Gutierrez J, Njoku V, Darie C Molecules. 2025; 30(3).

PMID: 39942749 PMC: 11820228. DOI: 10.3390/molecules30030645.

SMYD4 promotes MYH9 ubiquitination through lysine monomethylation modification to inhibit breast cancer progression.

Yang J, Cao J, Sun R, Zhou X, Chen Z, Liu B Breast Cancer Res. 2025; 27(1):20.

PMID: 39930544 PMC: 11812198. DOI: 10.1186/s13058-025-01973-3.

Functional Involvement of Signal Transducers and Activators of Transcription in the Pathogenesis of Influenza A Virus.

Liu S, Qiu F, Gu R, Xu E Int J Mol Sci. 2025; 25(24.

PMID: 39769350 PMC: 11677356. DOI: 10.3390/ijms252413589.

A comprehensive genome-based analysis identifies the anti-cancerous role of the anoikis-related gene ADH1A in modulating the pathogenesis of breast cancer.

Chen C, Guo S, Chai W, Yang J, Yang Y, Chen G Mol Genet Genomics. 2024; 299(1):108.

PMID: 39531174 DOI: 10.1007/s00438-024-02200-y.

References

Regua A, Aguayo N, Jalboush S, Doheny D, Manore S, Zhu D . TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers. Cancers (Basel). 2021; 13(10). PMC: 8150921. DOI: 10.3390/cancers13102340. View

Hou J, Schindler U, Henzel W, Ho T, Brasseur M, McKnight S . An interleukin-4-induced transcription factor: IL-4 Stat. Science. 1994; 265(5179):1701-6. DOI: 10.1126/science.8085155. View

Nakayama Y, Mimura K, Tamaki T, Shiraishi K, Kua L, Koh V . Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer. Int J Oncol. 2019; 54(6):2030-2038. PMC: 6521934. DOI: 10.3892/ijo.2019.4779. View

Lim C, Cao X . Structure, function, and regulation of STAT proteins. Mol Biosyst. 2007; 2(11):536-50. DOI: 10.1039/b606246f. View

Zhao Q, Liu Y, Wang T, Yang Y, Ni H, Liu H . MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling. Eur J Pharmacol. 2020; 884:173359. DOI: 10.1016/j.ejphar.2020.173359. View

Frank D, Mahajan S, Ritz J . Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999; 5(4):444-7. DOI: 10.1038/7445. View

Clarkson R, Boland M, Kritikou E, Lee J, Freeman T, Tiffen P . The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol Endocrinol. 2005; 20(3):675-85. DOI: 10.1210/me.2005-0392. View

Johnson K, Peck A, Liu C, Tran T, Utama F, Sjolund A . PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am J Pathol. 2010; 177(6):2971-83. PMC: 2993292. DOI: 10.2353/ajpath.2010.090399. View

Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng C . Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol. 2004; 24(18):8037-47. PMC: 515028. DOI: 10.1128/MCB.24.18.8037-8047.2004. View

10.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

11.

DiScala M, Najor M, Yung T, Morgan D, Abukhdeir A, Cobleigh M . Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. PLoS One. 2020; 15(6):e0234146. PMC: 7289443. DOI: 10.1371/journal.pone.0234146. View

12.

Ma J, Qin L, Li X . Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal. 2020; 18(1):33. PMC: 7048131. DOI: 10.1186/s12964-020-0527-z. View

13.

Boothby M, Gravallese E, Liou H, Glimcher L . A DNA binding protein regulated by IL-4 and by differentiation in B cells. Science. 1988; 242(4885):1559-62. DOI: 10.1126/science.3144043. View

14.

Oh E, Kim Y, An H, Sung D, Cho T, Farrand L . Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. Int J Cancer. 2018; 143(8):1978-1993. DOI: 10.1002/ijc.31585. View

15.

Di Mauro C, Rosa R, Damato V, Ciciola P, Servetto A, Marciano R . Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017; 116(11):1425-1435. PMC: 5520095. DOI: 10.1038/bjc.2017.116. View

16.

Sarma P, Ramaiah M, Pal D, Bhadra U, Bhadra M . A novel bisindole-PBD conjugate inhibits angiogenesis by regulating STAT3 and VEGF in breast cancer cells. Life Sci. 2016; 151:264-276. DOI: 10.1016/j.lfs.2016.03.024. View

17.

Chen W, Wang H, Cheng M, Ni L, Zou L, Yang Q . Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling. Biomed Pharmacother. 2018; 103:435-442. DOI: 10.1016/j.biopha.2018.04.076. View

18.

Neergheen V, Hip Kam A, Pem Y, Ramsaha S, Bahorun T . Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms. Semin Cancer Biol. 2020; 80:145-156. DOI: 10.1016/j.semcancer.2020.03.004. View

19.

Fu X, Kessler D, Veals S, Levy D, Darnell Jr J . ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc Natl Acad Sci U S A. 1990; 87(21):8555-9. PMC: 54995. DOI: 10.1073/pnas.87.21.8555. View

20.

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View